This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Alnylam Pharmaceuticals' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)

Stocks in this article: ALNY

Alnylam Pharmaceuticals, Inc. (ALNY)

Morgan Stanley Global Healthcare Conference

September 11, 2012, 01:30 pm ET


John Maraganore - CEO

Mike Mason - VP, Finance


Dave Friedman - Morgan Stanley


Dave Friedman - Morgan Stanley

Thanks everyone for joining us. Dave Friedman one of the biotech analyst and in terms of disclosures for myself and Morgan Stanley, you can look on and we’ve team from Alnylam up here; very exciting platform, RNAi company and more. And on the far side here I’ve got Mike Mason, VP of Finance and on the near side, John Maraganore, CEO. And so maybe if you guys want to give a brief sort of statement or overview about the company at all and then we can then just dive right in.

John Maraganore

Sure, David thanks and thanks for having us here at the conference. Alnylam is a RNAi therapeutics company that has focused from the beginning on developing small interfering RNA drugs and over the last many years, we really been focused on perfecting the technology so that we can achieve the optimization of these molecules, introducing drug-like properties into these molecules and ultimately delivering these molecules into the right cell types and tissues in the body to be able to harness the indigenous RNAi pathway to create important new medicines.

And I think it's fair to say that over the last two years in particular, the work that we've done on achieving delivery of small interfering RNAs to liver cells and documenting in human trials that we can in fact knock down targeting genes man with very robust pharmacological effects and I think that largely comes out of the work that we’ve done in our transthyretin amyloidosis program, but also the work we've done on our PCSK9 Hypercholesterolemia program.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs